Recommended standards for biochemical markers of myocardial damage: All Wales Clinical Biochemistry Audit Group

Annals of Clinical Biochemistry

Volumn 42, Issue 5, 2005, Pages 346-350

  Williams, E J ^a   Jones, C J H ^a   McDowell, I F W ^b   Tovey, J A ^c   Thomas, M A ^d   Wayte, A M O ^e   Brown, N ^f   Jenkins, G H ^g   Oleesky, D A ^b  

^a PRINCESS OF WALES HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c NEVILL HALL HOSPITAL   (United Kingdom)

^d CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^e YSBYTY GWYNEDD   (United Kingdom)

^f ROYAL GWENT HOSPITAL   (United Kingdom)

^g MORRISTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CREATINE KINASE; TROPONIN;

BIOCHEMISTRY; CLINICAL FEATURE; CONFERENCE PAPER; CREATINE KINASE BLOOD LEVEL; ELECTROCARDIOGRAM; HEALTH PRACTITIONER; HEART INFARCTION; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; QUALITY CONTROL; ST SEGMENT ELEVATION; THORAX PAIN;

BIOLOGICAL MARKERS; HUMANS; MYOCARDIAL INFARCTION; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 25144446203     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563054890042     Document Type: Conference Paper

References (23)

1. World Health Organisation. Report of the Joint International Society and Federation of Cardiology/World Health Organisation Task Force on Standardisation of Clinical Nomenclature and criteria for diagnosis of ischaemic heart disease. Circulation 1979; 59: 607-9
2. Collinson PO, Moseley D, Stubbs PJ, Carter GD. Troponin T for the differential diagnosis of ischaemic myocardial damage. Ann Clin Biochem 1993; 30: 11-6
3. Apple FS, Maturen AJ, Mullins RE, et al. Multicenter clinical and analytical evaluation of the AxSym troponin-1 immunoassay to assist in the diagnosis of myocardial infarction. Clin Chem 1999; 45: 206-12
4. Fox KM, Birkhead J, Wilcox R, et al. British Cardiac Society Working Group on the definition of myocardial infarction. Heart 2004; 90: 603-9
5. Ann Clin Biochem 2004;41:263-71
6. James S, Armstrong P, Califf R, et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUST-JV trial. Am J Med 2003; 115: 178-84
7. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40
8. Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial Infarction redefined - a consensus document for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-13
9. Venge P, Lagerqvist B, Diderholm E, et al. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). Am J Cardiol 2002; 89: 1035-41
10. Hickman PE, Koerbin G, Tate J. The reporting of cardiac troponin. Clin Biochem Rev 2003; 24: 99-108
11. Apple FS, Wu AHB. Myocardial infarction redefined: role of cardiac troponin testing (editorial). Clin Chem 2001; 47: 377-9
12. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes Jr R. National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999; 45:1104-21
13. Panteghini M, Pagani F, Yeo K-TJ, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations (on behalf of Committee on standardization of markers of cardiac damage of the IFCC). Clin Chem 2004; 50: 327-32
14. Apple FS, Quist HE, Doyle PJ, et al. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003; 49: 1331-6
15. Thomas MA, Singh G, Williams EJ, et al. A review of troponin assay performance in Wales - can the same (method dependent) decision limits be used in different sites? Ann Clin Biochem 2005; 42: 351-6
16. Collinson PO. Cardiac markers into the new millennium. Ann Clin Biochem 2000; 37: 109-13
17. Panteghini M, Apple FS, Christenson RH, et al. Recommendations on use of biochemical markers of cardiac damage in acute coronary syndromes. Scand J Clin Lab Invest 1999; 59(suppl 230): 103-12
18. Ross SM, Fraser CG. Biological variation of cardiac markers: analytical and clinical considerations. Ann Clin Biochem 1998; 35: 80-4
19. Collinson PO. Early diagnosis of myocardial infarction: why measure cardiac enzymes? J Clin Pathol 1998; 51: 2-4
20. Barsky AJ, Hochstrasser B, Coles NA, et al. Silent myocardial ischemia: is the person or the event silent? JAMA 1990; 264: 1132-5
21. Hillis GS, Oliner C, O'Neil BJ, et al. Coronary artery disease in patients with chest pain who have low-risk clinical characteristics and negative cardiac troponin I. Am J Emerg Med 2001; 19: 118-21
22. Tate J, Ward G. Interferences in immunoassay. Clin Biochem Rev 2004; 25: 105-20
23. Kontos MC, Shah R, Fritz LM, et al. Implications of different cardiac troponin levels for clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol 2004; 43: 958-65